市场调查报告书
商品编码
1022069

囊状纤维化症治疗药的全球市场:产业趋势,市场占有率、规模、成长率、机会及预测(2021年~2026年)

Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

囊状纤维化症治疗药的全球市场,预计从2015年到2020年显示强力的成长,从2021年到2026年之间以约10%的年复合成长率市场规模扩大。

全球囊性纤维化发病率的上升,以及该疾病诊断技术的改进,是推动市场成长的关键因素之一。此外,广泛采用囊肿纤维化跨膜传导调节蛋白(CFTR)作为治疗替代方案也促进了市场成长。此外,各种技术进步,例如个性化药物治疗,提高分子假体和疗效的创新药物的开发,成为另一种促进生长的因素。其他因素,包括医疗保健支出增加、健康意识的增强以及对囊性纤维化可用治疗方案的认识,预计将进一步推动市场。

本报告提供全球囊状纤维化症治疗药市场的相关调查,提供产业趋势,市场预测,各医药品分类、药物分子类型、给药途径、终端用户、地区的市场分析,竞争情形,主要企业的简介等资讯。同时更考虑COVID-19的不确定性,持续追踪并评估疫情对各种最终用途产业带来的直接及间接性影响。

目录

第1章 序文

第2章 范围与调查手法

第3章 摘要整理

第4章 简介

第5章 全球囊状纤维化症治疗药市场

  • 市场概要
  • 市场成果
  • COVID-19的影响

第6章 各医药品分类的市场区隔

  • 胰脏酵素补充品
  • 粘液溶解药
  • 支气管扩张药
  • CFTR调制器
  • 抗生素
  • 其他

第7章 各药物分子类型的市场区隔

  • 小分子药
  • 生技药品

第8章 各给药途径的市场区隔

  • 口服药
  • 吸入药

第9章 各终端用户市场区隔

  • 医院
  • 诊所
  • 其他

第10章 各地区的市场区隔

  • 北美
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 中东、非洲
    • 各国市场区隔

第11章 SWOT分析

第12章 价值链分析

第13章 波特的五力分析

第14章 价格指标

第15章 竞争情形

  • 市场结构
  • 主要企业
  • 主要企业的简介
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
目录
Product Code: SR1020E135_Report

The global cystic fibrosis therapeutics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body. Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further.

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc. Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the drug molecule type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cystic fibrosis therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2020
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2020
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2020
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million US$), 2021-2026
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million US$), 2021-2026
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players